Defining the stages of aggressive non-Hodgkin's lymphoma - A work in progress

New England Journal of Medicine

Volumn 352, Issue 12, 2005, Pages 1250-1252

  Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

AGE; ANATOMY; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DRUG SENSITIVITY; EDITORIAL; GENE EXPRESSION; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY; T CELL LYMPHOMA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; VINCRISTINE; VINDESINE;

EID: 15444371891     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048345     Document Type: Editorial

References (12)

1. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-6.
2. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-205.
3. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Vol. 3 of World Health Organization classification of tumors. Lyon, France: IARC Press, 2001.
6. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
7. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18.
8. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003;21:20-7.
9. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
10. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
11. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
12. Wilson HP, Pittaluga S, O'Connor P, et al. Rituximab may overcome Bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphoma. Blood 2001;98:343a. abstract.